skip to Main Content

Expert Shares Significance of PFS Benefit With PARP Maintenance in BRCA+ Metastatic Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Olaparib (Lynparza) improved progression-free survival (PFS) compared to placebo in patients with BRCA-mutant metastatic pancreatic cancer, based on data from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.

This randomized, double-blind, placebo-controlled phase III trial randomized 154 patients 3:2 to receive either the PARP inhibitor or placebo as maintenance therapy. Patients had to have a germline BRCA1 or BRCA2 mutation and responded to frontline platinum-based chemotherapy for at least 16 weeks.  Read more . . . 

Back To Top